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ABSTRACT 
Objective: In recent years studies have been conducted with the aim to 
investigate the extent to which recommendations for co-prescribing 
gastroprotective agents in prevention of NSAID-induced gastrointestinal 
complications are followed in clinical practice. However, only a few studies have 
also taken into consideration the recommended dose of gastroprotectives 
prescribed in NSAID-induced ulcer prophylaxis. The aim of our study was to 
evaluate the prevalence of concomitant use of gastroprotectives with NSAIDs in 
hospitalized patients, with emphasis on the recommended dose of 
gastroprotectives for ulcer prophylaxis.  
Method: This observational, cross-sectional, drug utilization study included all 
adult patients receiving NSAIDs hospitalized in the Clinical Hospital Center 
Zagreb on the day of the study. Data on age, sex, comorbidities, indications for 
NSAID use, type/dose of NSAIDs and gastroprotectives, history of 
gastrointestinal events, active gastrointestinal symptoms and risk factors were 
evaluated.  
Main outcome measure:  Study outcomes were: (1) prevalence of prescription 
of gastroprotectives among NSAID-users at risk; (2) prevalence of prescription 
of gastroprotective in recommended dose; (3) association between risk factors 
and prescription of GPAs.   
Results: The rates of gastroprotectives prescription were significantly higher in 
NSAID-users with concomitant risk factors as compared to patients without risk 
factors [47/70 (67,1%) and 8/22 (36,4%), respectively; p=0,01072].  However, 
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gastroprotection in recommended ulcer-preventive dose was low in both groups 
[8/70 (11,4%) and 9/92 (9,8%), respectively]. The number of concomitant risk 
factors did not increase the odds of receiving anti-ulcer therapy (odds ratio 
0,7279). Thirty-three percent of patients with concomitant risk factors were not 
prescribed gastroprotectives.  Ibuprofen, NSAID with the lowest risk of inducing 
gastrointestinal complications, was prescribed in only 2 patients. 
Conclusion: The results indicate high awareness among hospital physicians 
about possible NSAID- induced gastrointestinal complications, but insufficient 
knowledge about risk factors related to NSAID-induced gastrointestinal toxicity, 
recommended dose of gastroprotectives in NSAID-induced ulcer prophylaxis 
and gastrointestinal toxicity of different types of NSAIDs.  
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STATEMENTS 
• NSAID prescribing patterns and implementation of recommended 
preventive strategies in hospitals are considered important due to the 
more vulnerable patient population and their influence on prescribing 
habits among general medicine physicians. 
• The prevalence of gastroprotection in our study was relatively high, but 
when recommended daily dose of gastroprotective agents taken into 
consideration, the actual prevalence of gastroprotection was 
unacceptably low. 
• The evaluation of NSAID and gastroprotective agents prescription 
patterns, which were similar across all risk groups, could be contributed 
to insufficient knowledge about the gastrointestinal toxicity of different 
types of NSAIDs, as well as about the most effective gastroprotection 
strategy.  
• Further studies with the aim to assess the use of gastroprotective agents 
with NSAIDs in secondary care are needed. 
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Use of gastroprotective agents in recommended doses in hospitalized 
patients receiving NSAIDs: a drug utilization study 
 
INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly 
used medications1. A major factor limiting their use is gastrointestinal (GI) 
toxicity, ranging from dyspepsia to life-threatening events 2 3. It is estimated that 
up to 15-30 % of patients taking NSAIDs develop GI adverse effects4 5, and that 
significant GI events occur in 2-4% patients taking NSAIDs6.  
NSAIDs are exhibiting their effect by inhibition of cyclooxygenase (COX-1 and 
COX-2) enzymes. Non-selective NSAIDs inhibit both COX-1 and COX-2 to 
varying degrees, where the anti-inflammatory effect is derived from inhibition of 
COX-2, while the adverse effects arise from inhibition of COX-1 activity. 
Selective COX-2 inhibitors are therefore associated with less GI morbidity7 8 9. 
However, the recent safety concerns surrounding the entire class of COX-A 
inhibitors10, are resulting in the reestablishment of conventional, nonselective 
NSAIDs as a mainstay of clinical care for patients with musculoskeletal 
disorders. 
Factors associated with increased risk of NSAID-associated serious 
complications are history of ulcer complications, concomitant anticoagulant 
therapy, advanced age (>65 years), concomitant corticosteroid use, chronic 
major organ impairment, the use of high dose or multiple NSAIDs and severe 
rheumatoid arthritis11 12 13. Strategies in prevention of NSAID-induced GI events 
are: (1) acetaminophen as the first-line therapy in musculosceletal disorders14; 
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(2) use of less GI toxic NSAIDs; (3) use of the lowest effective dose of NSAID; 
(4) concomitant use of gastroprotective agents (GPAs) in patients with 
increased risk.  
Prevention of NSAID-induced GI morbidity by co-prescription of GPAs has been 
validated in many clinical studies15 16 17. The use of GPAs has focused on two 
approaches: prostaglandin replacement (misoprostol) and inhibition of acid 
secretion (proton pump inhibitors and histamine2-receptor antagonists). 
Misoprostol was of no relevance for our study since it is not approved in 
Croatia. Histamine2-receptor antagonists (H2RA) heal almost all NSAID ulcers 
when the patient discontinues NSAID use. However, in patients who continue 
NSAID use, H2RA in traditional doses are more effective in healing duodenal 
ulcers than gastric ulcers18 19. It appears that larger than traditional doses of 
H2RAs are more effective at NSAID-associated ulcer prevention20. Several 
studies have confirmed the superior efficacy of proton pump inhibitors (PPIs) in 
the short and longer-term prevention of NSAID-induced ulcers as compared to 
H2RA 17 21. However, prophylactic use of PPIs in all patients is unnecessary 
and cost-prohibitive22. 
Two recent systematic reviews have assessed the effectiveness of various 
GPAs against GI complications induced by NSAIDs use. A  Cochrane review by 
Rostom et al. assessed the effectiveness of H2RAs, PPIs and misoprostol 
against endoscopic ulcers, ulcer complications, symptoms and dropouts23. The 
results showed that all GPAs included prevented endoscopic ulcers. A 
systematic review by Hooper et al. assessed the effectiveness of H2RAs, PPIs 
and misoprostol plus non-selective NSAIDs, and COX-2 selective NSAIDs in 
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reducing serious GI complications, symptomatic ulcers, serious 
cardiovascular/renal disease, death, and improving quality of life. They found 
that misoprostol, COX-2 specific NSAIDs and probably PPIs significantly reduce 
the risk of symptomatic ulcers, and misoprostol and probably COX-2 selective 
NSAIDs significantly reduce the risk of serious GI complications. Data were 
insufficient to draw conclusions on effect of H2RAs compared with placebo on 
any primary outcomes. Endoscopic ulcers were significantly reduced in 
participants taking H2RAs compared to placebo. In half of the 15 studies 
included the dose of H2RAs was higher than the traditional dose24. These 
reviews and previous studies 5 Error! Bookmark not defined. 17 support the consensus 
that PPIs and high dises of H2RAs offer significant protection in patients 
receiving NSAIDs. 
The prevalence of co-prescription of GPAs with NSAIDs is estimated to be 20-
40%25 26. According to recommendations from professional societies such as 
The American College of Rheumatology27 38, patients with at least one 
gastrointestinal risk factor should receive NSAID plus a coprescribed protective 
agent. Several countries have established relevant clinical guidelines. However, 
the extent to which such guidelines are implemented in clinical practice is not 
known. There are only a few studies that have also taken into consideration the 
recommended dose of H2RAs when used in NSAID-ulcer prophylaxis20 28.  
Rational and evidence based drug prescribing is one of the main goals in 
pharmaceutical care. Underutilization, as well as inappropriate use of GPAs, 
can contribute to increased health costs29 30.  Only by optimal prescribing it is 
possible to control the rising share of these drugs in national drug budgets. It is 
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estimated that anti-ulcer drug prescriptions consume around 10% of the 
national drug budgets in Australia and England31 32 33. 
The purpose of this study was to evaluate not only the prevalence of 
concomitant use of GPAs with NSAIDs, but also the extent to which NSAID 
users receive therapy that really provides gastroprotection. Previous studies 
assessed the utilization of gastroprotective measures in primary care. The aim 
of our study was to assess the use of GPAs with NSAIDs in secondary care. 
The fact that most GI complications induced by NSAID therapy are occurring 
during the start of NSAID therapy makes the secondary care prescribing even 
more important. Although most prescribing takes place in general practice, the 
influence of secondary care prescribing on primary care prescribing is well 
recognized 34 35 36 37. 
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METHODS 
Study design 
We conducted an observational, cross-sectional study on November 11th, 2003. 
The study included all adult patients (aged >18 years) hospitalized in the 
Clinical Hospital Center Zagreb on the day of the study who received NSAIDs. 
An exclusion criterion was an indication for which gastroprotective drugs were 
indicated other than NSAID ulcer prophylaxis. A structured questionnaire was 
developed at the Division of Clinical Pharmacology with the aim to collect 
information on age, sex, reason for hospitalization, concomitant diseases, 
indications for use of NSAIDs or/and GPAs, type and dose of NSAIDs and 
GPAs prescribed, history of GI disease, presence of active GI symptoms and 
concomitant risk factors. On the day of the study, ten clinical pharmacologists 
and residents in clinical pharmacology visited all departments and collected 
data on all patients prescribed NSAIDs according to the prepared questionnaire.  
Informed oral consent was obtained from all patients prior to inclusion. The data 
collection was anonymous. Included were patients prescribed gastroprotectives 
as NSAID ulcer prophylaxis, which was determined by interview and/or 
reviewing clinical charts. Use of recommended gastroprotective strategy was 
defined as the co-prescription of PPIs in standard dose or H2RAs in double 
dose of the NSAID prescription. The co-prescription of an antacid or H2RA in 
standard dose was considered as less than recommended in NSAID ulcer 
prophylaxis.  
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Gastroprotective agents 
Prescribed GPAs included antacids (Al-hydroxide-Mg-carbonate gel), H2RA 
ranitidine and PPIs (omeprazole, pantoprazole, lansoprazole). The 
recommended daily doses of GPAs were defined as ranitidine 600 mg, 
omeprazole 20 mg, pantoprazole 40 mg and lansoprazole 30 mg. Lower doses 
of these drugs were classified as “less than recommended”. Antacids were 
considered inappropriate gastroprotective strategy in prevention of NSAID-
induced GI adverse effects. Misoprostol was not approved in Croatia at the time 
of the study.  
Identification of patients at high risk for NSAID-associated GI complications 
Factors that identified patients at high risk of developing NSAID associated 
complications were defined as age > 65 years, history of GI events, present GI 
symptoms (dyspepsia, gastritis), concomitant use of corticosteroids, 
anticoagulant therapy or of aspirin, serious co-morbidities, ≥2 prescribed 
NSAID, higher than recommended daily doses of NSAIDs. In patients with 1≥ 
risk factors the co-prescription of GPAs was considered recommended. 
Standard daily doses of NSAIDs were defined as ketoprofen 300 mg, diclofenac 
100 mg, indomethacin 50 mg, ibuprofen 1200 mg and piroxicam 20 mg.  
Outcomes 
Study outcomes were: (1) prevalence of GPAs prescription among patients at 
risk for NSAID-induced GI complications vs. patients not at risk; (2) prevalence 
of GPAs prescription in recommended doses; (3) estimation of the association 
between risk factors and prescription of GPAs.   
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Statistical analysis 
Standard descriptive statistics were used to describe the study population and 
their utilization of NSAIDs and GPAs. Means and Standard Deviations (SD) 
were calculated for age. The proportions of NSAID users with and without 
gastroprotective therapy in relation to concomitant risk factors and type of GPAs 
prescribed were calculated and compared using the chi-squared test. The 
relationship between co-prescription of GPAs and number of concomitant risk 
factors by estimation of odds ratio, was performed using the logistic regression 
model. All tabulations and statistical analysis were done using Statistica for 
Windows, Version 5.5, StatSoft, Inc. (2000). 
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RESULTS 
Out of 770 patients hospitalized on the day of the study 93 patients received 
NSAIDs. One patient with rheumatoid arthritis was prescribed a COX-2 
selective NSAID (rofecoxib). This patient was excluded being the only one 
receiving a selective COX-2 inhibitor.  
The mean age of patients receiving NSAIDs was 59 years, more than a half of 
the patients were aged over 65 (54,3%), and half of the patients were female 
(51,1%). In approximately two thirds of patients NSAIDs and GPAs were 
prescribed during hospitalization (72,7% and 80,0%, respectively). Seventy of 
92 patients had one or more concomitant risk factors (76,1%), which identified 
them as patients at high risk of developing NSAID associated complications, 
and almost half of them (45,7%) had ≥ 2 concomitant risk factors (Table 1). 
Insert Table 1. The most frequent indication for prescription of NSAIDs was 
analgesia [(postoperative pain, malignant pain, neurologic disorders, 
musculosceletal disorders, abdominal pain); 87,0%] and rheumatic disease 
(13,0%). 
The most frequently prescribed NSAID was ketoprofen (78,3%), followed by 
diclofenac, indomethacin, ibuprofen and piroxicam. Three patients were 
concomitantly prescribed 2 NSAID. All patients received NSAIDs in standard 
doses (except 3 patients taking concomitantly 2 NSAIDs). The distribution of 
NSAIDs by type was similar across risk groups (Table 2). Insert Table 2.  
Overall, GPAs were prescribed in 59,7% patients. The prevalence of GPA 
prescription was significantly higher in the subset of 70 NSAID users with 
concomitant risk factors, as compared to the subset of patients without risk 
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factors [47/70 (67,1%) and 8/22 (36,4%), respectively; p=0,01072].  However, 
only 9 NSAID users overall and 8 NSAID users with concomitant risk factors, 
received GPAs in the recommended ulcer-preventive dose [9/92 (9,8%) and 
8/70 (11,4%), respectively]. The number of concomitant risk factors did not 
increase the odds of receiving anti-ulcer therapy (odds ratio 0,7279; 95% CI: 
0,24-2,19). Thirty-three percent of patients with any risk factor present, and 31 
percent of patients with more than 2 concomitant risk factors, did not receive 
GPAs. Thirty-six percent of patients (8/22) without risk factors were receiving 
gastroprotectives. Individual risk factors identified in the study were age ≥65 
years, positive history of GI events, concomitant therapy with corticosteroids, 
present GI symptoms (including ulcer in one patient), therapy with ≥2 NSAID 
and concomitant use of aspirin. There was no significant difference in the 
prevalence of GPAs prescription between patients with a specific risk factor 
versus patients without the risk factor (Table 3). Insert Table 3.  
The most frequently prescribed GPA was ranitidine, prescribed in 81,8 % of 
patients receiving a GPA, followed by PPIs and antacids (14,5 % and 3,6%. 
respectively). However, in all but one patient ranitidine was prescribed in lower 
dose than recommended for ulcer prophylaxis. PPIs were prescribed in 
recommended dose in all patients. They typically were prescribed in NSAID 
users at risk for developing NSAID-induced GI complications (7/8 patients). 
Three patients were prescribed antacids as gastroprotective measure in ulcer 
prophylaxis, one patient in combination with ranitidine (Table 4). Insert Table 4.  
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DISCUSSION 
Although the prevalence of prescribing GPAs overall and in NSAID users at 
high risk was relatively high (59,8 and 67,1%) compared to similar studies 38 39 
40
 
41
 
42
, when recommended daily doses of GPAs were taken into consideration, 
the actual prevalence of gastroprotection was unacceptably low (9,8% and 
11,4%, respectively). High prevalence of GPA utilization with NSAIDs may be 
contributed to the high prevalence of concomitant risk factors and higher 
awareness of possible NSAID-induced GI effects among hospital physicians43 
44
. Higher prevalence of individual risk factors as compared to other studies 
could be contributed to the more vulnerable hospital population (more co-
morbidities, older age, concomitant therapy). Furthermore, the hospitalization 
itself could be considered a risk factor, but was not taken into account as a 
separate risk factor in this study.  Although the presence of any risk factor 
among NSAID users resulted in significantly higher prevalence of GPA 
prescription, the prescription rates of GPAs were similar across all risk groups. 
The number of concomitant risk factors did not increase the odds of GPA 
prescription. The high prevalence of GPA prescription without significant 
difference in prescription rates between different risk groups could be explained 
by awareness of possible NSAID-induced GI complications, but insufficient 
knowledge about individual risk factors related to increased risk.  
The most prescribed NSAID was ketoprofen, which is one of the NSAIDs with 
highest relative risk of inducing GI events. Ibuprofen, the NSAID with the lowest 
relative risk of inducing GI events12, was prescribed in only 2 patients. One 
patient with present duodenal ulcer (confirmed by endoscopy) was receiving 
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ketoprofen with co-prescription of a PPI. The prescription patterns of NSAIDs 
demonstrate lack of knowledge about differences in GI toxicity of various types 
of NSAIDs.  
All patients receiving PPIs were appropriately protected, since PPIs are 
effective in ulcer prophylaxis in their standard dose. H2RAs have to be taken in 
double dose to be effective in ulcer prophylaxis23.  Although PPIs are 
considered the appropriate gastroprotective drug in patients with high risk for 
NSAID-induced GI toxicity, due to their lower cost, in our hospital H2RAs are 
still the most prescribed GPAs (45/55; 81,8%). Only one patient received 
H2RAs in ulcer preventive dose. This indicates insufficient knowledge about 
dose recommendations of H2RAs when used in NSAID-ulcer prophylaxis. 
Antacids are not considered appropriate therapy in NSAID-induced ulcer 
prophylaxis. However, three patients received antacids in ulcer prevention, one 
patient in combination with ranitidine.  
Monitoring of GPA prescription strategies in NSAID users in hospitals is 
important due to their influence on prescribing habits in general practice 34 35 36 
37
, where the GPA prescription rate is low, ranging from 7,9-41,6%45 46. The risk 
for serious gastrointestinal complications seems to be related to the beginning 
of NSAID use47, and according to our results more then two thirds of patients 
were prescribed NSAIDs and GPAs during hospitalization.  
The methodological weaknesses of our study include lack of data on duration 
on NSAID therapy, long/short term prescription, concomitant drug therapy, as 
well as no categorization by indications for NSAID use (analgesia or rheumatic 
disease), no assessment of appropriateness of the NSAID prescription in the 
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individual patient, as well as no data on the extent of repeat prescribing of 
NSAIDs and GPAs in primary care. However, we believe that our study offers 
useful information on GPAs prescription strategies in NSAID users in the 
hospital setting, with the emphasis on the extent to which NSAID users receive 
recommended therapy that really provides gastroprotection. More studies 
assessing the use of H2RAs as ulcer-preventive drugs are needed, as well as 
studies dealing with the evaluation of GPAs use with NSAIDs in secondary 
care.   
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CONCLUSION 
Although we did not directly measure the knowledge of hospital physicians on 
the studied topic, the results of our study nevertheless indicate high awareness 
of possible NSAID induced GI complications among hospital physicians (high 
GPA prescription rate), but also insufficient knowledge about specific risk 
factors related to NSAID-induced toxicity, recommended dose of H2RAs in ulcer 
prophylaxis and GI toxicity of different types of NSAIDs. Although the 
prevalence of GPAs among NSAID users overall and in patients at high risk 
was relatively high, when recommended daily doses of GPAs were taken into 
consideration, the actual prevalence of gastroprotection was unacceptably low.  
More than 2/3 of patients receiving NSAIDs were prescribed NSAIDs and GPAs 
for the first time during hospitalization. Since secondary care prescribing has 
considerable influence on general practicioners’ prescribing, studies aimed at 
evaluation of the use of GPAs with NSAIDs in secondary care are needed. 
 
 
Use of gastroprotective agents in patients receiving NSAIDs 18 
AKNOWLEDGEMENTS 
None of the authors of this manuscript had any conflicts of interest connected to 
the conduct of the study.  
Use of gastroprotective agents in patients receiving NSAIDs 19 
FINANCIAL SUPPORT OF THE STUDY 
The study received no external funding.  
Use of gastroprotective agents in patients receiving NSAIDs 20 
Table 1 Basic characteristics. 
Baseline characteristics N (%) 
patients taking NSAIDs * 93/770 (12,1) 
patients included 92 
  
Age, Mean±SD 58,9±13,5 
  
 N (%) 
females 47 (51,1) 
age >65 50 (54,3) 
NSAIDs prescribed during hospitalization** 67/92 (72,8) 
GPAs prescribed during hospitalization† 44/55(80,0) 
  
no risk factor 22/92 (23,9) 
1 risk factor 38/92 (41,3) 
2 risk factors 20/92 (21,7) 
3 risk factors 8/92 (8,7) 
4 risk factors 4/92 (4,3) 
* including a patient who was prescribed rofecoxib; excluded from further 
evaluation 
** missing data for 15 patients  
† missing data for 3 patients  
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Table 2. NSAIDs prescription by risk factors. 
 
 
≥ 2 risk 
factors,  
N (%) 
1 risk 
factor, N 
(%) 
no risk 
factors,  
N (%) 
Total 
ketoprofen 22 (31) 30 (43) 18 (26) 70 
diclofenac 3 (25) 5 (42) 4 (33) 12 
indomethacin 2 (67) 1 (33) 0 (0) 3 
ibuprofen 0 (0) 2 (100) 0 (0) 2 
piroxicam  2 (100) 0 (0) 0 (0) 2 
diclofenac+indomethacin 1 (100) 0 (0) 0 (0) 1 
ketoprofen+indomethacin 1 (100) 0 (0) 0 (0) 1 
diclofenac+ketoprofen 1 (100) 0 (0) 0 (0) 1 
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Table 3. GPAs prescription by risk factors 
  
Number of 
patients 
Absent of GPA    
[N (%)] 
Less than 
recommended 
dose [N (%)] 
Recommended 
dose [N (%)] p-value* 
Total 92 37 (40) 46 (50) 9 (10)  
No risk factors 22 14 (64) 7 (32) 1 (4)  
Specific risk factors      
age >65 years 50 17 (34) 27 (54) 6 (12) n.s. 
history of GI disorders 23 8 (35) 11 (48) 4 (17) n.s. 
history of peptic ulcers 5 0 (0) 4 (80) 1 (20) n.s. 
presence of GI symptoms 14 4 (29) 8 (57) 2 (14) n.s. 
concomitant corticosteroids 
therapy 
16 5 (31) 9 (56) 2 (12) n.s. 
concomitant aspirin therapy 2 1(50) 1 (50) - n.s. 
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≥2 NSAIDs 3 0 (0) 3 (100) 0 (0) n.s. 
concomitant aspirin therapy 2 1 (50) 1 (50) 0 (0) n.s. 
Any risk factor 70 23 (33) 39 (56) 8 (11) p=0,01072 
≥2 risk factors 32 10 (31) 17 (53) 5 (16)      n.s.** 
1 risk factor 38 13 (34) 22 (58) 3 (8)  
2 risk factors 20 7 (35) 10 (50) 3 (15)  
3 risk factors 8 3 (37) 4 (50) 1 (13)  
4 risk factors 4 0 (0) 3 (75) 1 (25)  
* p values were calculated for difference in GPAs presription versus those without the specific risk factors 
** compared to NSAID users with 1 risk factor 
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Table 4. Prescription of gastroprotective agents by tipe and dose recommendation 
  
Number of 
patients No GPAs [N (%)] 
Less than recommended 
dose [N (%)] 
Recommended dose [N 
(%)] 
Total anti-ulcer therapy 92 37 (40) 46 (50) 9 (10) 
     
H2RAs 45  44 (98) 1 (2) 
PPIs 8  0 (0) 8 (100) 
antacids 3  3 (100) 0 (0) 
     
Anti-ulcer therapy in patients at risk 70 23 (33) 39 (56) 8 (11) 
     
H2RAs 38  37 (97) 1 (3) 
PPIs 7  0 7 (100) 
antacids* 2   1 (100) 0 (0) 
* 3 patients were receiving antacids, 1 patient in combination with H2RA and this patient is included in the H2RA group 
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